General
impact 16
Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1
Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1 Nature, Published online: 29 April 2026; doi:10.1038/s41586-026-10341-w The phase 1b NIVIPIT trial shows that in combined therapy with intravenou…
Why it matters
The timing matters: safety is converging with shifts in efficacy, which could amplify the downstream impact.